Segment Information (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment is as follows:

	Year Ended December 31, 2022
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net revenues	$	—		$	5,512	$	12,463		$	—			$	17,975
Gross profit		—			1,976		(3,666	)		—				(1,690	)
Direct expenses		75,379			1,699		10,859			56,261				144,198
Segment contribution		(75,379	)		277		(14,525	)		(56,261	)			(145,888	)
Indirect expenses										(120,288	)	(a)		(120,288	)
Loss from operations													$	(25,600	)
(a) Components of other
Change in fair value of contingent consideration liability										(126,277	)
Change in fair value of contingent stock consideration										186
Goodwill impairment										3,610
Amortization										2,193
Total other									$	(120,288	)

	Year Ended December 31, 2021
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net revenues	$	—		$	5,522		$	15,813	$	—			$	21,335
Gross profit		—			1,873			9,809		—				11,682
Direct expenses		85,107			2,119			8,450		64,018				159,694
Segment contribution		(85,107	)		(246	)		1,359		(64,018	)			(148,012	)
Indirect expenses										(38,953	)	(b)		(38,953	)
Loss from operations													$	(109,059	)
(b) Components of other
Change in fair value of contingent consideration liability										(41,145	)
Amortization										2,192
Total other									$	(38,953	)